Melissa Vera Ullerich - 16 Mar 2022 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Reporting relationship: Chief Communications Officer
Issuer ticker: SABS
Reported as of: 16 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Mar 2022, 21:15:35 UTC
Prior SEC filing: 22 Oct 2021
Source filing: View source filing
Reporting owner signature: /s/ Melissa Vera Ullerich

Key filing fact

Melissa Vera Ullerich filed Form 4 for SAB Biotherapeutics, Inc. (SABS) on 18 Mar 2022.

Key facts

This page summarizes Melissa Vera Ullerich's Form 4 filing for SAB Biotherapeutics, Inc. (SABS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Mar 2022, 21:15.

Change

Previous filing in this sequence was filed on 22 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SABS transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +16,405
Change %
Price: $0.000000
Shares after: 16,405
Date: 16 Mar 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,405
Exercise price: $1.78
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

Footnote F2

The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors.